Professional paper

Fixed combination perindopril-amlodipine – optimised treatment in hypertension and coronary artery disease.

Veronika Ljevar ; Krka, d. d., Novo mesto, Slovenija
Polona Knavs-Vrhunec ; Krka, d. d., Novo mesto, Slovenija
Breda Barbič-Žagar orcid.org/0000-0002-1173-7361 ; Krka, d. d., Novo mesto, Slovenija

Abstract

Hypertension is currently the biggest single risk factor contributing to global death. Despite the constantly improving treatments, only one third of patients who are treated have a normalisation of blood pressure (BP). Recent clinical trials suggest that the approach of using monotherapy for the control of hypertension is not likely to be successful in most patients. Combination therapy is preferred, based on the fact that multiple factors contribute to hypertension and achieving control of BP with a single agent acting through one particular mechanism may not be possible. Combining the medicines makes them available in a convenient dosing format and lowers the dose of individual components, thus reducing the side effects and improving compliance. Based on evidence from the Anglo-Scandinavian Cardiac Outcomes Trial Blood Pressure-Lowering Arm (ASCOT-BPLA), the combination of an angiotensin-converting enzyme (ACE) inhibitor with a calcium channel blocker (CCB) is one of the preferred therapeutic options. The combination perindopril-amlodipine is the only treatment among ACE inhibitor and CCB combinations that has been demonstrated to meet the primary objective of antihypertensive therapy, that is, overall reduction of hypertension-related death and morbidity. Krka is now the only generic company offering a fixed combination of perindopril and amlodipine and thus enabling effective treatment tailored to the individual needs of patients and physicians.

Keywords

hypertension; fixed combinations; blood pressure; perindopril; amlodipine

Hrčak ID:

94684

URI

https://hrcak.srce.hr/94684

Publication date:

24.9.2012.

Article data in other languages: croatian

Visits: 3.837 *